MTOR and breast cancer: Similar effects were also observed in canine mammary cancer cell lines that exhibit high basal Wnt/β-catenin activity, where treatment with dactolisib (dual pan-PI3Kα/γ/δ/β and mTOR inhibitor) enhanced TCF/LEF transcriptional activity, and CTNNB1 and AXIN2 mRNA expression [108].